To develop and commercialize novel oncology drug to treat KRAS-driven cancers

Boehringer Ingelheim

Lupin

Boehringer Ingelheim acquires Swiss biotech firm AMAL Therapeutics to expand its cancer immunology portfolio and leverage AMAL's KISIMA immunisation platform.

Targeting complex diseases with complex molecules

Large-molecule Therapeutics

Amal Therapeutics

Companies specializing in peptide-based treatments leverage short amino acid chains, known as peptides, to target and modulate various biological processes for therapeutic applications

Boehringer Ingelheim Venture Fund

Flyinghealth

Dopavision

City Hill Ventures

Xeraya Capital

Korea Investment Partners

Delos Capital

Madison Partners

Viron

UCB Ventures

BioCity Group

Rinri Therapeutics

V-Bio Ventures

AdBio partners

Pontifax

Omnes Capital

AgomAb Therapeutics

Companies that develop engineered proteins that can target specific proteins or cells in the body

To develop a rapid African swine fever (ASF) diagnostic test. The test would be used in combination with GNA's portable molecular diagnostic platform, and is aimed at supporting the fight against the worldwide spread of this deadly disease.

Promoting the health, well-being, and ethical treatment of animals

Animal Therapeutics

GNA Biosolutions

Companies that provide veterinary diagnostic services, which include a wide range of tests, procedures, and laboratory services to diagnose, monitor, and manage the health and well-being of animals. This includes laboratory testing, diagnostic imaging, endoscopy, and genetic testing.

To strengthen and expand efforts to bring new treatments for neuropsychiatric conditions, such as schizophrenia, by combining Boehringer Ingelheim's expertise in drug discovery and Vanderbilt University's research on brain circuitry modulation.

Vanderbilt University

New technologies are opening up mental health services to previously overbooked and underserved populations.

Mental Health Tech

Click Therapeutics develops software that provides prescription digital therapeutics (PDTs) for individuals diagnosed with mental health and chronic conditions. It's only nonprescription therapeutic, a smoking cessation product called Ckickotine, is commercially available and clinically validated despite not requiring FDA approval.&nbsp;The company leverages adaptive data science and machine learning algorithms to personalize content and ensure user engagement. Click’s programs attempt to change individual behavior through cognitive and neurobehavioral mechanisms and can be used independently or in conjunction with biomedical treatments. Users can download the app after being prescribed by a physician and activate it using a pharmacist-issued activation code. The treatments (missions for users) are usually between eight and 12 weeks long, and patients can interact with physicians during or after completing therapy.&nbsp;In March 2024, the company, in collaboration with Otsuka Pharmaceutical, launched Rejoyn, the first FDA-cleared prescription digital therapeutic for the adjunctive treatment of major depressive disorder (MDD) symptoms in adults aged 22 and older who are on antidepressant medication. Rejoyn utilizes cognitive emotional brain training exercises and cognitive behavioral therapy to help reduce depression symptoms.Additionally, as of September 2024, the company had several PDTs in the pipeline across a variety of therapeutic areas that were still in the development stage, including insomnia, schizophrenia, migraines, acute coronary syndrome, overactive bladder, obesity, and chronic lower back pain. The company's pipeline includes CT-155, a PDT for treating negative symptoms of schizophrenia, which received FDA Breakthrough Device designation in January 2024. Click is also developing CT-132, a PDT for episodic migraine prevention that received FDA Breakthrough Device designation in December 2022.&nbsp;In <a href="https://sp-edge.com/updates/29687">May 2024</a>, Click acquired assets from Better Therapeutics, including AspyreRx, an FDA-authorized PDT for type two diabetes, to accelerate its development initiatives in obesity and cardiometabolic diseases.Key customers and partnershipsClick partnered with Magellan Health for clinical coaching and pharmacy benefits management in 2016. Additionally, the company has collaborated with Otsuka (December 2018) in a deal worth USD 302 million to develop and commercialize a PDT for the treatment of MDD, as well as a partnership with Boehringer Ingelheim (September 2020) to develop and commercialize a PDT to aid in the treatment of schizophrenia.Furthermore, in September 2023, Click initiated a partnership with Indivior to develop a prescription digital therapeutic for opioid use disorder.&nbsp;

Pet ownership is at an all time high in the United States and the pet care economy is booming.

Pet Care Tech

<div>
 
 Otto (formerly 
 <a href="https://sp-edge.com/updates/21435">
 TeleVet)
 </a>
 is a web and mobile app solution provider that connects veterinary clinics with pet owners. Once set up through the 
 Otto
 platform, pet owners can send virtual consultations to clinics for review. Veterinarians can include virtual follow-up appointments as a part of their service offerings. As of June 2020, the 
 Otto
 platform was used by around 6,500 veterinarians in the US.
 
 
 The platform is offered on a SaaS bais for USD 99 per month for annual contracts and USD 129 per month for monthly contracts.
 
 
 Key customers and partnerships
 
 
 In March 2022, the company 
 <a href="https://sp-edge.com/updates/8932">
 partnered with Boehringer Ingelheim,
 </a>
 a pharmaceutical company, to expand Otto&rsquo;s services by becoming Boehringer Ingelheim&rsquo;s preferred veterinary health technology platform in the US. As part of the partnership, Boehringer Ingelheim invested an undisclosed amount in Otto; the company intends to use the funds and utilize Boehringer Ingelheim&rsquo;s commercial team for product development.
 
 
 Funding and financials
 
 
 In June 2020, the company raised USD 5 million in Series A funding led by Mercury Fund. The funds are expected to be used to accelerate the growth of the platform and the team. 
 
</div>

NBE-Therapeutics AG was a privately-owned Swiss biotech company based in Basel, founded in 2012. The company focused on developing next-generation immune-stimulatory antibody-drug conjugates (ADCs) for cancer treatment. Its proprietary iADC platform created highly potent and safe immune-stimulatory ADCs with an anthracycline payload, inducing a long-lasting immunological anti-tumor effect. This platform demonstrated unprecedented preclinical efficacy and safety across multiple pipeline programs.
NBE's lead asset, NBE-002, targeted the ROR1 receptor and successfully completed GLP toxicology studies, supporting the initiation of a first-in-human study. In 2020, NBE-002 entered phase 1 clinical trials for triple-negative breast cancer, lung cancer, and other solid tumors and lymphomas. The company leveraged proprietary technologies for antibody discovery (Transpo-mAb Display), site-specific payload conjugation (SMAC-Technology), and a novel anthracycline-based toxin platform.
In December 2020, Boehringer Ingelheim acquired NBE-Therapeutics for EUR 1.18 billion, including contingent milestones. The acquisition provided Boehringer Ingelheim access to NBE's innovative iADC platform and expanded its cancer immunology portfolio with the goal of developing powerful combination therapies.

Ilara Health brings accurate and affordable diagnostics to rural Africans through miniature, AI-powered diagnostic devices that are integrated through a proprietary technology platform and distributed directly to primary care doctors.

Otto provides an integrated mobile app extension to existing veterinarian practice management systems. The Otto app allows two-way communication between clients and veterinary staff, enabling telemedicine, appointment scheduling, digital prescriptions and much more.

Yale Cancer Center is a cancer treatment center that provides prevention, detection, diagnosis, and treatment for cancer. They provide treatments for patient care,oncology, and hematology.

Click Therapeutics develops and commercializes software as medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.

Proxygen is reshaping the druggable space. Their company harnesses technology and know-how to exploit this potential, thereby redefining the borders of the druggable target space. They developed rational discovery assays that, for the first time, enabled the identification and development of novel glue degraders at scale, putting them at the forefront of charting this unexplored chemical space.

NBE-Therapeutics is a privately owned Swiss, Basel-based biotech company that was founded in 2012. It is dedicated to developing cancer therapies to increase survival and improve the quality of life for cancer patients worldwide. The company’s immune-stimulatory therapies are based on a proprietary, highly differentiated Antibody-Drug Conjugate platform. Its ADC platform creates potent and safe immune-stimulatory ADCs with an anthracycline payload, not only directly targeting tumor cells but also inducing a long-lasting immunological anti-tumor effect.

MabVax is a clinical stage biopharmaceutical company focused on the commercialization of proprietary anti-cancer immunotherapies resulting from two integrated and successful technology platforms. The first is a series of vaccines developed at Memorial Sloan-Kettering Cancer Center (MSKCC) and licensed to MabVax. Two of the company’s lead cancer vaccines are currently undergoing proof of concept Phase II multi-center clinical trials for the treatment of soft tissue sarcoma and ovarian cancer. Both trials have received $2MM or more in federal grant monies. The second is a human antibody discovery platform developed internally and based on the protective immune responses generated from patients who have been successfully immunized against targeted cancers with the licensed vaccines. The company’s lead human antibody candidate is undergoing preclinical evaluation for development against colon, pancreatic and breast cancers and has received $1.1MM in federal grant monies.

Graybox Solutions is a growing company based in Montreal that develops software solutions for healthcare. Its mission is to provides advanced digital solutions that can help address the numerous healthcare challenges, reducing the payer burden associated with chronic care management.

PrometheraÂ® Biosciences is a biopharmaceutical company, spin-off of the UniversitÃ© Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology.  PrometheraÂ® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers.  PrometheraÂ® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Boehringer Ingelheim is a research-driven group of companies that focuses on researching, developing, manufacturing, and marketing pharmaceuticals that improve health and quality of life.

<div> Boehringer Ingelheim is a leading research-based pharmaceutical company founded in 1885 in Ingelheim, Germany. The family-owned business focuses on developing innovative medicines for human and animal health. Boehringer Ingelheim operates across three core business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In the Human Pharma segment, the company concentrates on therapeutic areas such as cardiology, oncology, neurology, and immunology. Its product portfolio includes medications like SPIRIVA for respiratory diseases, PRADAXA (an oral anticoagulant), and diabetes treatments SYNJARDY and JENTADUETO. Boehringer Ingelheim has a robust research pipeline, with approximately 50% dedicated to biopharmaceuticals and the other half focusing on small molecules. The Animal Health business offers a wide range of vaccines, parasite control products, and therapeutics for pets, horses, and livestock. Boehringer Ingelheim's animal health division has been operating for over a century, with deep roots in the US. In the Biopharmaceutical Contract Manufacturing division, the company provides customized solutions for the development and manufacturing of biologic drugs. It operates advanced facilities like the Biologicals Development Centre (BDC) in Biberach, Germany, which consolidates research, development, and production capabilities for biopharmaceuticals. Boehringer Ingelheim has made significant investments in expanding its global biopharmaceutical development network, including a new chemical innovation plant (CIP) in Ingelheim that will enhance the company's capabilities for producing active pharmaceutical ingredients for clinical trials. As of 2024, Boehringer Ingelheim employed over 53,000 people worldwide and served more than 130 markets. </div>

Saniona receives SEK 5.7 million milestone payment from Boehringer Ingelheim collaboration

Companies that offer specialized therapeutics for the diagnosis, treatment, and management of cancer in animals. This includes areas such as cancer diagnosis, surgery, chemotherapy, and immunotherapy.

Companies that develop vaccines and drugs for pets and livestock based on advanced research and biotechnologies such as DNA technology, with a specific focus on the treatment and prevention of diseases and medical conditions in animals.

Companies that use regenerative techniques and technologies to promote tissue repair, regeneration, and healing in animals. This involves stem cell therapy, platelet-rich plasma (PRP) therapy, tissue engineering, gene therapy, and wound healing treatments.

Companies that provide specialized treatments aimed at extending the lifespan and improving the overall health and quality of life of animals, including companion animals and livestock. These approaches are designed to address the challenges of aging, prevent age-related diseases, and enhance the well-being of aging animals.

Artificial intelligence is identifying and testing new therapies faster than ever.

AI Drug Discovery

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 Canada-based AI-drug discovery company Phenomic AI has partnered with pharmaceutical company Boehringer Ingelheim to discover components in stroma-rich cancers.
 Under the agreement, Phenomic will receive $9 million upfront and potential earnings of over $500 million in milestones and royalties.
 The collaboration will focus on using Phenomic's scTx single-cell transcriptomics platform to improve treatment for stroma-rich cancers, such as colorectal and pancreatic cancers. Boehringer Ingelheim will license Phenomic's targets and handle non-clinical, clinical development, and commercialization of associated cancer therapies.
</div>

Boehringer Ingelheim

Featured Industries

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless